September 2019 News & Views: Read articles about: survey to help AMCP establish Leg-Reg priorities, Partnership Forum on digital therapies, Foundation Symposium to explore impact of technology on oncology, the Western Regional Conference, and more.
House Speaker Nancy Pelosi Introduces Drug Pricing Bill H.R.3; Hill Days: AMCP Takes Message to
House and Senate Offices; SAMHSA Issues New Proposed Rule to Modernize 42 CFR Part 2
This JMCP article describes how discoveries made through a validation process improved the accuracy and transparency of a previously published budget impact analysis model that overestimated utilization following a formulary change.
A retrospective claims data analysis published in JMCP found that patients with metastatic melanoma treated with PD-1 had substantially lower costs than patients treated with other first line agents.
AMCP Submits Comments to Senate Finance Committee on Drug Pricing Bill HHS Announces Action Plan for Safe Importation of Prescription Drugs; CMS Issues 2020 Physician Fee Schedule; AMCP Submits Comments on Reducing Administrative Burdens in Health Care
White House Withdraws ‘Rebate Rule’; House Holds Hearings and Markups on Bills Addressing Drug Pricing Transparency; CMS Issues New Proposed Rule on ePA; CMS Seeks Comments on Reducing Administrative Burdens in Health Care AMCP Takes Steps to Improve Prior Authorization on Processes
Senate Drug Pricing Bill Unveiled; House Passes CREATES Act; AMCP Comments on Biosimilar and Interchangeable Insulin Products; AMCP Comments on Proposed Rule on Information Blocking; CMS Issues RFI on Reducing Administrative Burden to 'Put Patients Over Paperwork'; AMCP’s PA and UM Concepts in Managed Care Pharmacy Is Available in JMCP